VALLEY FORGE, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that Keri Mattox will join the Company as Vice President, Corporate & Investor Relations, effective January 3, 2017. In this role, Ms. Mattox will assume responsibility for the Company’s relationships with the analyst and investor community, reporting directly to Tim G. Guttman, Executive Vice President and Chief Financial Officer.
Ms. Mattox succeeds Barbara A. Brungess, currently Vice President, Corporate & Investor Relations, who has announced that she is leaving the Company, effective December 31, 2016, to pursue other opportunities.
“I am delighted to have Keri lead our investor relations efforts going forward. In addition to the investor relations and healthcare industry experience she brings to AmerisourceBergen, Keri has established a great reputation and many strong relationships across the financial community,” said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. “We look forward to Keri’s contributions and support as AmerisourceBergen continues to pursue its long-term growth strategies in the global pharmaceutical supply chain.”
“I also want to thank Barbara for her leadership and dedication to AmerisourceBergen during the 16 years she has been with the Company,” Collis continued. “Barbara has made a significant impact on AmerisourceBergen during her tenure and helped us build and solidify relationships with the investment community. Her integrity, sound judgment and industry expertise have served AmerisourceBergen and our shareholders extremely well. It has been a pleasure working with Barbara, and we wish her all the best.”
Ms. Mattox brings over 15 years of investor relations and corporate communications experience spanning both corporate roles and public relations firms. She has significant experience within the specialty, generics and biotech pharmaceutical sectors. Most recently, Ms. Mattox served as Senior Vice President, Investor Relations & Corporate Public Affairs with Endo International, a role she assumed in 2015 following Endo’s acquisition of Auxilium Pharmaceuticals, where she led the investor relations function. At Endo, she was responsible for investor relations, corporate communications and government affairs. Ms. Mattox started her career in journalism with positions at the Washington Post and Hearst Newspapers before transitioning into public relations and then the pharmaceutical industry.
Ms. Mattox graduated magna cum laude with a bachelor’s degree in Political Science from Boston University and has her master’s degree in Journalism from the University of Maryland.
About AmerisourceBergen
AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human and animal health. With over $145 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 19,000 people. AmerisourceBergen is ranked #12 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
